Themis Medicare Promoter Pledge Rises to 7.60% in 2026

Themis Medicare Limited has reported fresh promoter share pledges during October 2026. Vividhmargi Investments Private Limited, a promoter entity, pledged 25 lakh equity shares on October 27, 2026. The disclosure said the pledge was created in favour of CTL Trusteeship Limited in relation to non-convertible debentures, or NCDs. This followed a pledge of 15 lakh equity shares by the same promoter entity on October 22. The latest transaction took the total encumbered shares to 7.60% of Themis Medicare's share capital. The company manufactures Active Pharmaceutical Ingredients, or APIs, and formulations, and sells pharmaceutical products in India and international markets.

Latest pledge disclosure

The October 28 disclosure stated that Vividhmargi Investments created a pledge on 25 lakh Themis Medicare shares. These shares represent 2.71% of the company's total share capital. CTL Trusteeship Limited is the entity in whose favour the encumbrance was created. The stated purpose was to secure NCD-related obligations. The disclosure was made under Regulation 31 of the SEBI Substantial Acquisition of Shares and Takeovers Regulations, 2011. It also referred to Regulation 28(3), which covers disclosures of reasons for promoter encumbrance. The company's trading status was listed as active in the available data.

Earlier October transaction

Before the latest disclosure, Vividhmargi Investments had pledged 15 lakh equity shares on October 22, 2026. That transaction represented a 1.63% stake in Themis Medicare. It was also created in favour of CTL Trusteeship Limited to secure a borrowing facility. Following that pledge, the total encumbered share capital stood at 4.89%. The October 27 pledge added another 2.71 percentage points of share capital to the encumbrance. The two reported October transactions therefore cover 40 lakh shares in aggregate. The disclosures identify the promoter entity and the secured party, while the available information does not state the size or terms of the underlying borrowing or NCDs.

Key disclosed figures

Promoter holding remains unchanged

Themis Medicare's promoter holding stood at 67.11% as of the September 2026 shareholding data provided. The promoter stake was unchanged at 67.11% in March, June and September 2026. It was also recorded at 67.11% in December 2025. Earlier data show a gradual movement from 67.26% in March 2021 to the present reported level. The fresh disclosures relate to an encumbrance on shares and do not state a sale of promoter shares. As a result, the reported pledge transactions should be distinguished from changes in promoter ownership. The available holding trend indicates that the overall promoter stake has remained broadly stable in recent quarters.

Why pledged shares matter to investors

A pledge allows a shareholder to use shares as security for a financing arrangement while retaining ownership, subject to the terms of that arrangement. For listed companies, promoter encumbrance disclosures are relevant because they provide information about shares linked to borrowings or debt instruments. Themis Medicare's latest filing specifies CTL Trusteeship as the pledgee and refers to NCDs for the October 27 transaction. The previous October filing cited a borrowing facility. Investors can track such disclosures alongside the promoter shareholding pattern to understand the extent of shares under encumbrance. The data provided also flags that a significant proportion of promoter holdings is pledged. However, the disclosures do not state any transfer, invocation, or sale of the pledged shares.

Regulatory disclosure framework

The October filings were reported under Regulation 31 of the SEBI SAST Regulations, 2011. This framework requires disclosures regarding promoter encumbrances in listed companies. The filing on the latest transaction also cited Regulation 28(3), which requires disclosure of reasons for an encumbrance. These disclosures make the identity of the promoter entity, the number of shares, the date and the pledgee available to the market. The documents record October 22 and October 27 as the dates on which the pledges were created. The announcements were reported on October 24 and October 28, respectively. No separate operational update from Themis Medicare was included in the supplied information.

Business context for Themis Medicare

Themis Medicare is engaged in the manufacture of APIs and formulations. Its business includes manufacturing and selling pharmaceutical products in India and internationally, according to the company information provided. The latest announcements concern the promoter entity's financing-related encumbrance rather than a change in the company's product portfolio or operating activities. No revenue, profit, production, regulatory approval or share-price figure was included in the supplied data. The last updated share price was shown only as an incomplete reference, without a number. Therefore, no stock-price movement or direct financial-performance impact can be quantified from the available information. The factual development for investors is the increase in disclosed encumbered share capital to 7.60%.

Timeline of October disclosures

What investors can monitor next

The latest reported position is that 7.60% of Themis Medicare's share capital is encumbered following the October 27 transaction. The promoter holding level in the September 2026 pattern was 67.11%. Future exchange disclosures can show whether the number of pledged shares changes, whether any encumbrance is released, or whether there is a change in promoter ownership. Investors may also review subsequent filings for additional details on the financing arrangements, where disclosed. For now, the reported facts are limited to the two October pledges, their stated purposes, and the cumulative encumbered share capital. The company continues to be listed as active. The next relevant update would be any fresh regulatory disclosure by the promoter entity or Themis Medicare.